FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Invention discloses novel heterodimeric fusion proteins IL-15/IL-15Pα - Fc and their use in combination with antibodies to PD-1 or to PD-L1 in immunotherapy of various oncological diseases.
EFFECT: heterodimeric fusion proteins IL-15 / IL-15Pα-Fc and their use are disclosed.
31 cl, 214 dwg, 6 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| HETERODIMERIC FC-FUSED PROTEINS IL15/IL15Rα | 2017 |
|
RU2779938C2 |
| BISPECIFIC PROTEINS AND METHODS OF THEIR PRODUCTION | 2017 |
|
RU2745648C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
